RxDoctor Payments Data

Sharad Goel, MD

Nephrology · Fairfield, OHNPI 1861438657

Payments from drug & device makers

$1,036in general payments, 2019–2025

Across 20 payments — averaging $51.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$171
  • Amgen$163
  • AstraZeneca$160
  • Alnylam Pharmaceuticals Inc.$122
  • Baxter Healthcare$115
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$97
  • plus $209 from 6 others

What the payments were for

  • Food & beverage$92990%
  • Education$10710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,036 in reported general payments places this provider in the 45th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$159,175
Medicare patients
414
Services billed
1,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl13$40,359
FarxigaDapagliflozin Propanediol19$14,500
VeltassaPatiromer Calcium Sorbitex16$14,196
EliquisApixaban15$9,857
AuryxiaFerric Citrate12$5,357
Sevelamer Carbonate22$2,677
Calcitriol238$2,632
Nifedipine ErNifedipine92$2,540
Allopurinol67$2,222
Tacrolimus14$1,896
Calcium Acetate31$1,258
Metoprolol Succinate71$1,023
Losartan Potassium97$859
Torsemide51$851
Indapamide96$791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$160$14,50019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 450 nephrology providers in Ohio.

Other nephrology in Fairfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →